Danazol
DrugHigh dose FP1198 applied once daily to both breasts for 6 treatment cycles.
NCT Number: NCT01105793
The purpose of this study is to determine the safety of topical FP1198 for the treatment of moderate to severe cyclic breast pain (cyclic mastalgia) and to examine the clinical activity of FP1198.
Looking for future studies?
Notify Me18 year and older
Female
Interventional
Phase 2
Women's Health Care, San Diego, California, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
High dose FP1198 applied once daily to both breasts for 6 treatment cycles.
Time frame: six months
FemmePharma Global Healthcare, Inc.
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05717894
Breast Diseases, Fibrocystic Breast Disease
Almaty, Almaty Region, Kazakhstan
View Trial DetailsNCT00826488
Breast Cancer, Breast Diseases
St Louis, Missouri, United States
View Trial DetailsNCT00999921
Benign Breast Disease, Breast Diseases
Kolkata, West Bengal, India
View Trial DetailsNCT00967681
Breast Diseases, Breast Fibrocystic Disease
Havana, La Habana, Cuba
View Trial Details